ASH 2019 | Allo-HSCT for CLL in the era of novel agents
Lindsey Roeker
• 7 Dec 2019
The approvals of ibrutinib, venetoclax, and PI3K inhibitors have led to fewer allogeneic hematopoietic stem cell transplantation (allo-HSCT) procedures for chronic lymphocytic leukemia (CLL). Lindsey Roeker, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the retrospective cohort study that examined CLL patients who underwent allo-HSCT following novel agent therapy. Data demonstrate that allo-HSCT remains a viable curative strategy that can overcome adverse CLL characteristics such as TP53 aberration and complex karyotype. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
